



Innovating for  
affordable healthcare

## Shilpa Medicare Limited

### Corporate & Admin Office :

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,  
Raichur-584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

Dated: 18 Feb, 2021

To,  
**Bombay Stock Exchange Limited,**  
Corporate Relationship Department,  
Phiroze Jeejeebhoy Towers,  
27th Floor, Dalal Street,  
Mumbai. 400001.

To,  
**The National Stock Exchange of India Limited,**  
Exchange Plaza,  
Bandra Kurla Complex,  
Banda East,  
Mumbai. 400051

**Subject:** Import Alert Issued by USFDA to Shilpa Medicare's Formulation's Manufacturing Unit at Pharma SEZ, TSIIIC, Polepally, Jadcherla, Mahbubnagar, Telangana, India

**Ref:** Disclosure pertaining to regulation 30 of the SEBI (LODR) regulations.

**Ref Stock Code:** NSE:SHILPAMED/BSE-530549

Dear Sir/Madam,

Further to our Letter Dated 10 October, 2020, (informing about receipt of Warning Letter), we wish to inform you that the Company has received an Import Alert 66-40 on February 17, 2021, pursuant to the USFDA inspection of the Unit 4, Jadcherla, Telangana facility from Feb 13 – 20 and Feb 24-25, 2020.

We also wish to inform you that three products have been exempted from the Import Alert – Azacitidine for Injection, Cyclophosphamide Capsules and Erlotinib Tablets.

We are committed to address the concerns raised by the USFDA and will work with the USFDA to resolve these issues at the earliest. We uphold quality and compliance with utmost importance and are committed to maintaining cGMP and quality standards across all Shilpa facilities.

Please take this information on record for doing the needful.

Thanking you,

Yours faithfully,

  
**V V Krishna Chaitanya**  
Company Secretary and Compliance Officer

